Valiant Organics Limited — PPTs, 03-12-2024: Investor Presentation

**Financial Highlights:** Valiant Organics reported operational revenue of INR 3,281 Mn for Q2-FY25, down 12.2% year-over-year. The operating EBITDA came in at INR 182 Mn, reflecting an EBITDA margin of 5.55%. The profit after tax (PAT) was reported at INR (131) Mn, equating to an EPS of INR (4.68).

**Strategic Initiatives and Growth Drivers:** The company focuses on specialty chemicals with strong demand in various sectors such as agrochemicals and pharmaceuticals. With six manufacturing units and a total production capacity of 70,000 TPA, Valiant remains one of the leading players in chlorophenol derivatives.

**Business Developments:** Recent challenges include a 6% decline in sales volume in Q2 due to reduced demand across key segments and significant price corrections affecting performance. This downturn was exacerbated by sluggish demand for paracetamol and intense competition from Chinese suppliers impacting PAP margins.

**Market Position and Competitive Advantage:** Valiant’s diverse client base and significant production capabilities position it strongly in the specialty chemicals market, although recent operating pressures necessitate close monitoring.

**Investor Implications:** With a market cap of approximately INR 11,120 Mn, investors should watch closely for recovery signs in demand and pricing stability, as current market conditions present both risks and potential opportunities for recovery in the upcoming quarters.